Table II.

Analysis of Internal Contents During In Vitro Release Testing

Time (day)	% TAFa released (wt%; means ± SD)b	Wt% TAF remaining in the implantf (wt%; means ± SD)c	Wt% monophenyl PMPA in implant (wt%; means ± SD)c	Extracted mass of TAF in the implant (mg; means ± SD)c	Purity of TAF in the implant (mol %; mean ± SD) c
0	0.0 ± 0.0	100	0	16.2 ± 0.4	100
30	17.5 ± 0.8	70.4 ± 4.7	4.8 ± 0.4	11.4 ± 0.7	91.5 ± 0.2
45	29.1 ± 1.4 d	57.7 ± 2.8	4.9 ± 0.1	9.4 ± 0.6	89.6 ± 0.5
60	40.2 ± 2.0 e	50.2 ± 2.6	5.1 ± 0.4	8.2 ± 0.5	88.0 ± 0.9

^aTAF equivalent

^bn = 10

^cn = 3

^dAverage of days 42 and 49

^eAverage of days 56 and 63

^f150 μm EG-85A with a core formulation weight ratio of 96:2:2 TAF:NaCl:MgSt; swollen implant core volume was ~350 μL